Why Is Axon (AXON) Down 15% Since Last Earnings Report?
Axon (AXON) reported earnings 30 days ago. What's next for the stock?
Axon Plunges 31.1% in 6 Months: Should You Hold or Fold the Stock?
AXON's 31% slide contrasts with strong device and software growth as rising costs, debt and valuation cloud near-term sentiment.
Axon Stock Faces Steep Valuation Risk: Could It Fall Another 30%?
Axon Enterprise (AXON) shares have dropped by 26.6% within a month, falling from $732.23 on October 31, 2025, to $537.75 currently. What lies ahead?
Can Axon Maintain EBITDA Margin Momentum Amid Cost Pressures?
AXON's rising margins, fueled by strong TASER and platform sales, support an upgraded 2025 EBITDA outlook despite cost pressures.
Has Axon Stock Been Good for Investors?
Axon adapted its business model to become a winner. The company continues to evolve, painting an optimistic picture of the future.
AXON's Software & Services Growth Picks Up: Can the Momentum Sustain?
Axon's surging Software & Services revenues and stronger 2025 outlook spotlight rising demand for digital evidence tools and premium features.
Axon Enterprise, Inc (AXON) Is a Trending Stock: Facts to Know Before Betting on It
Axon (AXON) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
3 High-Quality Stocks Getting Stomped by the Market. Time to Buy?
The broader market has surged to record highs in 2025, with the S&P 500 up about 14% year-to-date.
AXON's Connected Devices Growth Picks Up: More Upside to Come?
Axon's Connected Devices segment surges on strong TASER 10 and Body 4 demand, driving 24% revenue growth.
Investors Heavily Search Axon Enterprise, Inc (AXON): Here is What You Need to Know
Axon (AXON) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Wall Street Bulls Look Optimistic About Axon (AXON): Should You Buy?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Axon's Q3 Earnings Miss Estimates & Revenues Beat, 2025 View Up
AXON posts mixed Q3 results as revenues surge on TASER and software demand, but higher costs pressure earnings; raises full-year 2025 outlook.
